ADDI celebrates one year of achievements
On 17 November 2020, a coalition of partners including the US Alzheimer’s Association, Gates Ventures
EPAD
Demonstrating the usefulness of a two-stage approach in characterising the evolution of correlated cognitive and clinical outcomes
A key challenge for the secondary prevention of Alzheimer’s dementia is the need to identify
Neuronet launches its social media campaign “Programme impact analysis – where we are and where we need to go”
The Neuronet project is setting up an efficient platform to boost collaboration across research projects
Neuronet convenes 7th meeting of its Scientific Coordination Board
On 21 October, the Innovative Medicines Initiative (IMI) funded Neuronet Coordination and Support Action convened
Job opportunity for a research technician working with EPAD samples
Applications are invited for the post of research technician to provide laboratory support to a
Neuronet Working Groups emphasise the importance of effective collaboration to overcome obstacles linked to patient privacy and data sharing
As a coordination and support action, Neuronet has been designed to enhance the impact and
EPAD-AMYPAD Imaging Workshop
On 17 June, the Innovative Medicines Initiative (IMI) projects EPAD and AMYPAD organised a virtual
Communication representatives of neurodegeneration research projects exchange on best practices
On 7 May, representatives of 12 Innovative Medicines Initiative neurodegeneration research projects met virtually to
Explore the AD Workbench to access the European Prevention of Alzheimer’s Dementia study data
As previously announced, the latest and final EPAD dataset called Version.IMI (V.IMI) is now available
Spotlight on early-career researchers: a Neuronet interview with Colin Birkenbihl
In this Neuronet interview, we speak to Colin Birkenbihl, a doctoral candidate at the Fraunhofer